Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIDHE: Ivosidenib plus azacitidine in newly diagnosed IDH1-mutant AML ineligible for intensive chemotherapy
2022-501709-11-00Phase 3Authorised
- Sponsor
- Servier
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of ivosidenib and azacitidine in acute myeloid leukemia (AML), sponsored by Servier. Planned start Apr 2023; status: authorised.
02
Drugs
ivosidenibazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2022-501709-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501709-11-00.